Detalhe da pesquisa
1.
Ultrasound-guided lymph node fine-needle aspiration for evaluating post-vaccination germinal center responses in humans.
STAR Protoc
; 4(4): 102576, 2023 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37733596
2.
Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial.
Sci Transl Med
; 15(692): eade9078, 2023 04 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37075127
3.
Bivalent and Monovalent SARS-CoV-2 Variant Vaccine Boosters Improve coverage of the known Antigenic Landscape: Results of the COVID-19 Variant Immunologic Landscape (COVAIL) Trial.
Res Sq
; 2023 May 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37205592
4.
Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial.
Nat Med
; 29(9): 2334-2346, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37640860
5.
SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses.
medRxiv
; 2022 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35898343
6.
The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals.
J Immunol
; 182(5): 3318-26, 2009 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19234231
7.
Comparison of biological activity of human anti-apical membrane antigen-1 antibodies induced by natural infection and vaccination.
J Immunol
; 181(12): 8776-83, 2008 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19050299
8.
Progress towards the development of malaria vaccines.
Trends Parasitol
; 22(7): 292-5, 2006 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-16707275
9.
Implication of respiratory syncytial virus (RSV) F transgene sequence heterogeneity observed in Phase 1 evaluation of MEDI-534, a live attenuated parainfluenza type 3 vectored RSV vaccine.
Vaccine
; 31(26): 2822-7, 2013 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-23602668
10.
Translational sciences approach to RSV vaccine development.
Expert Rev Vaccines
; 12(9): 1047-60, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24053398
11.
Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of age.
PLoS One
; 8(10): e77104, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24204744
12.
Template protocol for clinical trials investigating vaccines--focus on safety elements.
Vaccine
; 31(47): 5602-20, 2013 Nov 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-23499603
13.
Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children.
Pediatr Infect Dis J
; 31(2): 109-14, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21926667
14.
A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide® ISA 720.
PLoS One
; 6(9): e24413, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21949716
15.
Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials.
PLoS One
; 5(10): e13755, 2010 Oct 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-21060780
16.
Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults.
Vaccine
; 28(10): 2236-2242, 2010 Mar 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-20051276
17.
Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.
Vaccine
; 28(31): 5135-44, 2010 Jul 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-19737527
18.
Quantitative detection of Plasmodium falciparum DNA in saliva, blood, and urine.
J Infect Dis
; 199(11): 1567-74, 2009 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19432544
19.
Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya.
PLoS One
; 4(3): e4708, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19262754
20.
Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.
PLoS One
; 4(4): e5254, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19390585